secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dermata Therapeutics, Inc. (DRMA)
CIK:        0001853816
Form:       8-K
Filed at:   2025-11-18T23:59:59+00:00
Accession:  0001493152-25-023942
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 1.02
LLM model:  deepseek-v4-flash:cloud@v2

Dermata terminates Villani license, pivots to OTC skin care
-----------------------------------------------------------

- Terminated license agreement with Villani Inc.; effective 90 days after Nov 17, 2025 notice.
- Eliminates future milestone payments of up to $40.5M and single-digit royalties.
- Strategic shift: will commercialize OTC skin care; withdrew XYNGARI IND.
- License covered exclusive rights to sponge-based products for skin disease treatments.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1853816/000149315225023942/0001493152-25-023942-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1853816/000149315225023942/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-023942

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer